# Nuclide record docetaxel-then-lu177-psma (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/docetaxel-then-lu177-psma/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "docetaxel-then-lu177-psma" ;
  schema:name "Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617"@en ;
  schema:description "In the trial that got 177Lu-PSMA-617 (Pluvicto) approved, everyone had already been treated with a taxane chemotherapy drug like docetaxel and with a hormone pill first. That is the treatment order the approval is based on, though a newer trial is now testing whether Pluvicto can be used earlier, before chemotherapy."@en ;
  schema:url <https://nuclide.cc/pairings/docetaxel-then-lu177-psma/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa2107322>, <https://jnm.snmjournals.org/content/63/6/823>, <https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.TPS211> ;
  nuclide:tag "prostate cancer", "treatment sequencing", "radioligand therapy" ;
  nuclide:related <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/>, <https://nuclide.cc/key-papers/paper-vision-nejm-2021/>, <https://nuclide.cc/people/michael-morris/>, <https://nuclide.cc/people/oliver-sartor/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:pairs <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/drugs/pluvicto/> .